316 related articles for article (PubMed ID: 29735542)
21. ΔNp73 overexpression promotes resistance to apoptosis but does not cooperate with PML/RARA in the induction of an APL-leukemic phenotype.
Lucena-Araujo AR; Coelho-Silva JL; Pereira-Martins DA; Thomé C; Scheucher PS; Lange AP; Paiva HH; Hemmelgarn BT; Morais-Sobral MC; Azevedo EA; Franca-Neto PL; Franca RF; Silva CL; Krause A; Rego EM
Oncotarget; 2017 Jan; 8(5):8475-8483. PubMed ID: 28035072
[TBL] [Abstract][Full Text] [Related]
22. PCGF2 negatively regulates arsenic trioxide-induced PML-RARA protein degradation via UBE2I inhibition in NB4 cells.
Jo S; Lee YL; Kim S; Lee H; Chung H
Biochim Biophys Acta; 2016 Jul; 1863(7 Pt A):1499-509. PubMed ID: 27030546
[TBL] [Abstract][Full Text] [Related]
23. Ten-eleven translocation 2 demethylates the
Li X; Wu C; Shen Y; Wang K; Tang L; Zhou M; Yang M; Pan T; Liu X; Xu W
J Biol Chem; 2018 Jun; 293(26):10059-10070. PubMed ID: 29773648
[TBL] [Abstract][Full Text] [Related]
24. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2.
Ko M; Huang Y; Jankowska AM; Pape UJ; Tahiliani M; Bandukwala HS; An J; Lamperti ED; Koh KP; Ganetzky R; Liu XS; Aravind L; Agarwal S; Maciejewski JP; Rao A
Nature; 2010 Dec; 468(7325):839-43. PubMed ID: 21057493
[TBL] [Abstract][Full Text] [Related]
25. Missense mutations in PML-RARA are critical for the lack of responsiveness to arsenic trioxide treatment.
Goto E; Tomita A; Hayakawa F; Atsumi A; Kiyoi H; Naoe T
Blood; 2011 Aug; 118(6):1600-9. PubMed ID: 21613260
[TBL] [Abstract][Full Text] [Related]
26. Loss of neuronal Tet2 enhances hippocampal-dependent cognitive function.
Pratt KJB; Shea JM; Remesal-Gomez L; Bieri G; Smith LK; Couthouis J; Chen CP; Roy IJ; Gontier G; Villeda SA
Cell Rep; 2022 Nov; 41(6):111612. PubMed ID: 36351399
[TBL] [Abstract][Full Text] [Related]
27. TET2 repression by androgen hormone regulates global hydroxymethylation status and prostate cancer progression.
Takayama K; Misawa A; Suzuki T; Takagi K; Hayashizaki Y; Fujimura T; Homma Y; Takahashi S; Urano T; Inoue S
Nat Commun; 2015 Sep; 6():8219. PubMed ID: 26404510
[TBL] [Abstract][Full Text] [Related]
28. PML/RARA inhibits expression of HSP90 and its target AKT.
Piredda ML; Gaur G; Catalano G; Divona M; Banella C; Travaglini S; Puzzangara MC; Voso MT; Lo-Coco F; Noguera NI
Br J Haematol; 2019 Mar; 184(6):937-948. PubMed ID: 30536958
[TBL] [Abstract][Full Text] [Related]
29. Ten-Eleven Translocation-2 (Tet2) Is Involved in Myogenic Differentiation of Skeletal Myoblast Cells in Vitro.
Zhong X; Wang QQ; Li JW; Zhang YM; An XR; Hou J
Sci Rep; 2017 Mar; 7():43539. PubMed ID: 28272491
[TBL] [Abstract][Full Text] [Related]
30. Acetylation Enhances TET2 Function in Protecting against Abnormal DNA Methylation during Oxidative Stress.
Zhang YW; Wang Z; Xie W; Cai Y; Xia L; Easwaran H; Luo J; Yen RC; Li Y; Baylin SB
Mol Cell; 2017 Jan; 65(2):323-335. PubMed ID: 28107650
[TBL] [Abstract][Full Text] [Related]
31. Accelerated degradation of PML-retinoic acid receptor alpha (PML-RARA) oncoprotein by all-trans-retinoic acid in acute promyelocytic leukemia: possible role of the proteasome pathway.
Yoshida H; Kitamura K; Tanaka K; Omura S; Miyazaki T; Hachiya T; Ohno R; Naoe T
Cancer Res; 1996 Jul; 56(13):2945-8. PubMed ID: 8674046
[TBL] [Abstract][Full Text] [Related]
32. Induction of DEAD Box helicase 5 in early adipogenesis is regulated by Ten-eleven translocation 2.
Cho M; Lee E; Shon J; Choi MJ; Park JH; Park YJ
Biochim Biophys Acta Mol Cell Biol Lipids; 2020 Jul; 1865(7):158684. PubMed ID: 32169654
[TBL] [Abstract][Full Text] [Related]
33. A novel PAD4/SOX4/PU.1 signaling pathway is involved in the committed differentiation of acute promyelocytic leukemia cells into granulocytic cells.
Song G; Shi L; Guo Y; Yu L; Wang L; Zhang X; Li L; Han Y; Ren X; Guo Q; Bi K; Jiang G
Oncotarget; 2016 Jan; 7(3):3144-57. PubMed ID: 26673819
[TBL] [Abstract][Full Text] [Related]
34. Characterisation of the PML/RAR alpha rearrangement associated with t(15;17) acute promyelocytic leukaemia.
Grimwade D; Solomon E
Curr Top Microbiol Immunol; 1997; 220():81-112. PubMed ID: 9103677
[TBL] [Abstract][Full Text] [Related]
35. Role of PML and PML-RARalpha in Mad-mediated transcriptional repression.
Khan MM; Nomura T; Kim H; Kaul SC; Wadhwa R; Shinagawa T; Ichikawa-Iwata E; Zhong S; Pandolfi PP; Ishii S
Mol Cell; 2001 Jun; 7(6):1233-43. PubMed ID: 11430826
[TBL] [Abstract][Full Text] [Related]
36. Leukemia with distinct phenotypes in transgenic mice expressing PML/RAR alpha, PLZF/RAR alpha or NPM/RAR alpha.
Rego EM; Ruggero D; Tribioli C; Cattoretti G; Kogan S; Redner RL; Pandolfi PP
Oncogene; 2006 Mar; 25(13):1974-9. PubMed ID: 16331271
[TBL] [Abstract][Full Text] [Related]
37. TRIB3 Promotes APL Progression through Stabilization of the Oncoprotein PML-RARα and Inhibition of p53-Mediated Senescence.
Li K; Wang F; Cao WB; Lv XX; Hua F; Cui B; Yu JJ; Zhang XW; Shang S; Liu SS; Yu JM; Han MZ; Huang B; Zhang TT; Li X; Jiang JD; Hu ZW
Cancer Cell; 2017 May; 31(5):697-710.e7. PubMed ID: 28486108
[TBL] [Abstract][Full Text] [Related]
38. Recurrent
Osumi T; Tsujimoto SI; Tamura M; Uchiyama M; Nakabayashi K; Okamura K; Yoshida M; Tomizawa D; Watanabe A; Takahashi H; Hori T; Yamamoto S; Hamamoto K; Migita M; Ogata-Kawata H; Uchiyama T; Kizawa H; Ueno-Yokohata H; Shirai R; Seki M; Ohki K; Takita J; Inukai T; Ogawa S; Kitamura T; Matsumoto K; Hata K; Kiyokawa N; Goyama S; Kato M
Cancer Res; 2018 Aug; 78(16):4452-4458. PubMed ID: 29921692
[TBL] [Abstract][Full Text] [Related]
39. Effects of arsenic on modification of promyelocytic leukemia (PML): PML responds to low levels of arsenite.
Hirano S; Watanabe T; Kobayashi Y
Toxicol Appl Pharmacol; 2013 Dec; 273(3):590-9. PubMed ID: 24135626
[TBL] [Abstract][Full Text] [Related]
40. Autophagy contributes to therapy-induced degradation of the PML/RARA oncoprotein.
Isakson P; Bjørås M; Bøe SO; Simonsen A
Blood; 2010 Sep; 116(13):2324-31. PubMed ID: 20574048
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
